
Eupraxia’s September-quarter loss came in slightly below expectations. But the result does little to answer the bigger question for this clinical-stage biotech: what will its December trial update show?
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) reported a fiscal third-quarter 2026 loss of C$0.33 per share for the period ended September 30, compared with an estimated loss of C$0.36. That’s an 8.3% positive surprise. The company remains unprofitable, with trailing 12-month EPS of -C$1.49. For investors, clinical progress and financing are likely to matter more than one quarter’s loss per share. Eupraxia expects an interim analysis from its EP-104GI Phase 2b RESOLVE trial in December and says its cash runway extends into the second half of 2028.
Recent earnings trend
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
Market cap
$710.35M
52W high
$13.08
52W low
$7.85
1W change
-20.97%
Beta
1.33
Analyst Price Targets
Based on analyst covering EPRX · as of Nov 18, 2026
Wall Street analysts forecast EPRX stock price to rise 184.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.43
+184.9% Upside
Previously C$16.33 on Sep 28, 2026
Current Price
C$6.12
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
85.7%
Annualized
90-Day Vol
81.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$7.34
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$8.27 | C$6.15 – C$11.12 |
| 60 trading days | C$7.79 | C$5.13 – C$11.84 |
| 90 trading days | C$7.34 | C$4.40 – C$12.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 8 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 1 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-12-31 | 2027-03-16 | — | -0.2800 | — |
| 2026-09-30 | 2026-11-10 | -0.3300 | -0.3600 | +8.3% |
| 2026-06-30 | 2026-08-11 | -0.3200 | -0.3200 | +0.0% |
| 2026-03-31 | 2026-05-07 | -0.3201 | -0.1900 | -68.5% |
| 2025-12-31 | 2026-03-12 | -0.5000 | -0.2200 | -127.3% |
| 2025-09-30 | 2025-11-04 | -0.2700 | -0.2700 | +0.0% |
Investor takeaway: EPRX’s earnings beat was modest. It doesn’t mean the company is profitable or change its clinical-stage profile. Eupraxia has beaten estimates in one of its last four reported quarters; the other three were in line with or below estimates. The December interim analysis is the next major clinical catalyst. The company has also established an at-the-market equity program, giving it another financing option. Investors should consider the trial update and potential share dilution alongside the earnings result.
C$0.33 loss per share
Eupraxia reported a loss of C$0.33 per share, C$0.03 narrower than the C$0.36 estimate. That’s an 8.3% positive surprise. Trailing 12-month EPS remains -C$1.49.
Bull case
Eupraxia has enrolled all 120 patients in the blinded Phase 2b portion of its EP-104GI trial. The company expects an interim analysis in December and reiterated that its cash runway extends into the second half of 2028. That gives it time to advance the program without an immediate stated need for financing. The quarterly loss also came in below the estimate.
Bear case
Eupraxia is still reporting losses, and the small EPS beat matters less than the trial results that will shape the outlook for this clinical-stage company. It has missed estimates in three of its last four reported quarters, including a larger-than-expected loss in March 2026. The ATM equity program gives the company another way to raise funds, but issuing shares could dilute existing investors. EPRX.TO also closed at C$6.12, below its 50-day and 200-day moving averages.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.

Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.



